UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

COVID-19 vaccine platforms: Delivering on a promise?

Human vaccines & immunotherapeutics, 2021-09, Vol.17 (9), p.2873-2893

2021

Volltextzugriff (PDF)

Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in Staphylococcus aureus

Journal of Bacteriology, 2007-02, Vol.189 (3), p.1025-1035

2007

Volltextzugriff (PDF)

Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections

Nature medicine, 2004-03, Vol.10 (3), p.243-245

2004

Volltextzugriff (PDF)

Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces

Antimicrobial Agents and Chemotherapy, 2003-11, Vol.47 (11), p.3407-3414

2003

Volltextzugriff (PDF)

Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of Staphylococcus aureus

Journal of Bacteriology, 2007-10, Vol.189 (20), p.7316-7325

2007

Volltextzugriff (PDF)

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

The Lancet infectious diseases, 2019-05, Vol.19 (5), p.487-496

2019

Volltextzugriff (PDF)

Identification of In Vivo–Expressed Antigens of Staphylococcus aureus and Their Use in Vaccinations for Protection against Nasal Carriage

The Journal of infectious diseases, 2006-04, Vol.193 (8), p.1098-1108

2006

Volltextzugriff (PDF)

Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model

Antimicrobial Agents and Chemotherapy, 2003-05, Vol.47 (5), p.1589-1597

2003

Volltextzugriff (PDF)

Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo

Antimicrobial Agents and Chemotherapy, 2007-02, Vol.51 (2), p.475-482

2007

Volltextzugriff (PDF)

Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2879-2886

2009

Volltextzugriff (PDF)

Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus

Antimicrobial Agents and Chemotherapy, 2005-08, Vol.49 (8), p.3256-3263

2005

Volltextzugriff (PDF)

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

Antimicrobial agents and chemotherapy, 2017-03, Vol.61 (3)

2017

Volltextzugriff (PDF)

Differential roles of sortase-anchored surface proteins and wall teichoic acid in Staphylococcus aureus nasal colonization

International journal of medical microbiology, 2008-07, Vol.298 (5), p.505-513

2008

Volltextzugriff (PDF)

Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice

Journal of antimicrobial chemotherapy, 2009-07, Vol.64 (1), p.94-100

2009

Volltextzugriff (PDF)

The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin

Cell host & microbe, 2007-05, Vol.1 (3), p.199-212

2007

Volltextzugriff (PDF)

Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection

Anaerobe, 2018-10, Vol.53, p.30-33

2018

Volltextzugriff (PDF)

A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis

Pediatrics (Evanston), 2011-08, Vol.128 (2), p.271-279

2011

Volltextzugriff (PDF)

SYN-004 (Ribaxamase), an Oral β-Lactamase, Prevented Clostridium Difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2B Clinical Trial

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1309-S1309

2017

Volltextzugriff (PDF)

Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model

Journal of antimicrobial chemotherapy, 2007-11, Vol.60 (5), p.1051-1059

2007

Volltextzugriff (PDF)

Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics

International journal of toxicology, 2016-05, Vol.35 (3), p.309-316

2016

Volltextzugriff (PDF)

In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood

Antimicrobial Agents and Chemotherapy, 2003-11, Vol.47 (11), p.3613-3615

2003

Volltextzugriff (PDF)

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies

Clinical drug investigation, 2016-09, Vol.36 (9), p.725-734

2016

Volltextzugriff (PDF)

Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

Infection and drug resistance, 2020-01, Vol.13, p.2521-2535

2020

Volltextzugriff (PDF)

Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C‐terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer

Molecular microbiology, 2002-01, Vol.43 (1), p.207-215

2002

Volltextzugriff (PDF)

Antibody against the Carboxyl Terminus of Intimin α Reduces Enteropathogenic Escherichia coli Adherence to Tissue Culture Cells and Subsequent Induction of Actin Polymerization

Infection and Immunity, 2005-04, Vol.73 (4), p.2541-2546

2005

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(44)
Buchkapitel
(1)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

COVID-19 vaccine platforms: Delivering on a promise?

Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in Staphylococcus aureus

Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections

Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces

Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of Staphylococcus aureus

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

Identification of In Vivo–Expressed Antigens of Staphylococcus aureus and Their Use in Vaccinations for Protection against Nasal Carriage

Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model

Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo

Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

Differential roles of sortase-anchored surface proteins and wall teichoic acid in Staphylococcus aureus nasal colonization

Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice

The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin

Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection

A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis

SYN-004 (Ribaxamase), an Oral β-Lactamase, Prevented Clostridium Difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity in a Phase 2B Clinical Trial

Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model

Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics

In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies

Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C‐terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer

Antibody against the Carboxyl Terminus of Intimin α Reduces Enteropathogenic Escherichia coli Adherence to Tissue Culture Cells and Subsequent Induction of Actin Polymerization

Suchergebnisse filtern